A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma

Phase 2

Ziopharm